407. Minimum Manufacturing Costs, National Prices and Estimated Global Availability of New Repurposed Therapies for COVID-19

BACKGROUND: Currently, only dexamethasone, tocilizumab and sarilumab have conclusively been shown to reduce mortality of COVID-19. No drug for prevention or treatment in earlier stages of COVID-19 are yet found, with previously promising drugs such as hydroxychloroquine and remdesivir have been show...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Junzheng, Levi, Jacob, Ellis, Leah, Hill, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690668/
http://dx.doi.org/10.1093/ofid/ofab466.608

Ejemplares similares

Ejemplares similares